Cholesterol clinical trials at UCSF
2 research studies open to eligible people
Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
open to eligible people ages 6-11
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to <12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
San Francisco, California and other locations
Inclisiran in Children With Homozygous Familial Hypercholesterolemia
open to eligible people ages 2-11
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).
San Francisco, California and other locations
Our lead scientists for Cholesterol research studies include Martin Thelin.
Last updated: